1 edition of Cost effectiveness of influenza vaccination. found in the catalog.
Cost effectiveness of influenza vaccination.
by Congress of the U.S., Office of Technology Assessment, For sale by the Supt. of Docs., U.S. G.P.O. in Washington, D.C
Written in English
|Contributions||United States. Congress. Office of Technology Assessment.|
|LC Classifications||RA644.I6 C67 1981|
|The Physical Object|
|Pagination||viii, 67 p. ;|
|Number of Pages||67|
|LC Control Number||81600183|
The high cost of influenza illness suggests that further efforts are required to increase influenza vaccination uptake in the U.S. to help reduce this burden. Potential conflict of interests M.S. Stockwell was a co-investigator but received no financial support for an unrelated, investigator-initiated grant from the Pfizer Medical Education by: Nearly 70 years later, the public and some health care workers still have questions regarding influenza vaccine safety, efficacy, effectiveness, and cost-effectiveness of vaccination of adults, even though multiple studies and a review of the influenza vaccine data for healthy adults have convincingly revealed that vaccination is effective in Cited by: 6.
The results of a cost-effectiveness analysis conducted in the early s suggest that influenza vaccination of healthy working adults could be highly cost-effective although it did not find vaccination to be a cost saving for adults younger than 65 years. 7 That study, however, did not incorporate indirect costs associated with productivity Cited by: The cost per QALY saved in this analysis is somewhat lower than that established in previous studies of the overall cost-effectiveness of the influenza vaccine in children, 10,18 likely associated with the fact that we focused on a specific site-based program rather than total vaccination rates across all settings, but is still comparable with Author: Rebecca J. Hart, Michelle D. Stevenson, Michael J. Smith, A. Scott LaJoie, Keith Cross.
No vaccine is % effective but evidence shows that the flu vaccine provides a good level of protection in healthy people. What type of vaccines does Priceline Pharmacy provide? The flu vaccine for , the Quadrivalent Flu Vaccine, includes the four . Cost effectiveness of infant vaccination for rotavirus in Canada. Rotavirus is the main cause of gastroenteritis in Canadian children younger than five years of age, resulting in significant morbidity and cost. The present study provides evidence on the cost-effectiveness of two alternative rotavirus vaccinations available in Canada.
Introduction to pneumatics.
Farewell to Valley Forge.
160th anniversary of Bibliotheca Bogoriensis
Studies in the Intellectual History of Tokugawa Japan (East Asian Studies)
classical dictionary of Hindu mythology and religion, geography, history and literature.
CEA directory of writing programs in the United States and Canada
Hymns in Christian worship.
Bibliography on polymers in concrete.
struggles for Poland
Breaking the Rules (Candelight Ecstasy Supreme)
Images of a lost Eden
Motion pictures, 1950-1959.
Cost-Effectiveness of Vaccines • Cost-effectiveness depends on several major factors among others IN THE LOCAL CONTEXT – Impact of the disease • Spread and Clinical Severity • Changes for every epidemic – Efficacy / effectiveness of the vaccine • To the actual circulating strain – Cost of the vaccine • Cost to societyFile Size: KB.
Costs. The model predicts that the vaccination program costs (vaccine acquisition and administration) would increase by $ million, with a $ million reduction in influenza-related costs for IIV4 compared with IIV3/LAIV3 ($ million direct medical and $ million indirect) (Table 2).Excluding vaccination program costs, all cost categories are predicted to be reduced with IIV4 Cited by: Influenza vaccine effectiveness for all vaccine types, Influenza B viruses; Age group (years) Influenza positive Total Influenza positive (% Vaccinated) Influenza negative Total Influenza negative (% Vaccinated) Adjusted VE % Adjusted 95% CI; All ages: 64 (48) (56) 34 (, 62).
We estimated cost-effectiveness of annually vaccinating children not at high risk with inactivated influenza vaccine (IIV) to range from US $12, per quality-adjusted life year (QALY) saved for children ages 6–23 months to $, per QALY saved for children ages 12–17 years.
Inwhen the vaccine virus differed from the predominant circulating viruses, vaccine efficacy against serologically confirmed influenza illness was 50% (P). In this season, vaccination did not reduce ILI, physician visits, or lost workdays; the net societal cost was $ per person compared with no by: Seasonal Influenza Vaccine Effectiveness, - CDC.
U.S. Flu Vaccine Effectiveness Networks. CDC has been working with researchers at universities and hospitals since the flu season to estimate how well flu vaccine works through observational studies using laboratory-confirmed flu as the outcome. Objective.
Intranasal influenza vaccine has proven clinical efficacy and may be better tolerated by young children and their families than an injectable vaccine. This study determined the potential cost-effectiveness (CE) of an intranasal influenza vaccine among healthy children.
Methods. We conducted a CE analysis of data collected between and during a prospective 2-year Cited by: With restricted health care budgets, evidence of cost-effectiveness is increasingly important to support publically funded health-care services. The objective of this study was to systematically review and appraise published economic evaluations of influenza immunization programs and describe their scope and diversity.
Methods Cited by: SinceVE studies looking at how well the flu vaccine protects against medically attended illness have suggested that when vaccine viruses and circulating flu viruses are well-matched, flu vaccines provide better protection against influenza B or influenza A (H1N1) viruses than against influenza A (H3N2) viruses.
Get this from a library. Cost effectiveness of influenza vaccination. [United States. Congress. Office of Technology Assessment.;]. Two-way sensitivity analysis on influenza illness rate and vaccine effectiveness (IIV) resulted in changes in the cost-effectiveness ratio from a decrease in 11% for a season with a high influenza illness rate (35%) and high vaccine effectiveness (IIV) to an increase of more than a factor of 30 for seasons with a low influenza illness rate and low vaccine effectiveness (IIV).Cited by: ated (intranasal) influenza vaccine (LAIV) for healthy per-sons ages 5–49 years, which has a higher list price than the inactivated (injected) vaccine but is also potentially more effective (6,7).
Previous studies have examined the cost-effectiveness of influenza vaccination in various age groups (8–10). However, these studies may have been. An RCT that compared a high-dose, inactivated influenza vaccine (containing four times the standard amount of influenza antigen) to standard dose vaccine in persons aged 65 years or older during the and influenza seasons found that rates of laboratory-confirmed influenza were 24% lower (95% CI: ) among persons who received.
Most children with influenza are treated in the primary care setting, and the cost-effectiveness of influenza vaccination of children has not been fully established. We used a decision analysis model to assess the cost-effectiveness of influenza vaccination Cited by: Maciosek MV, Solberg LI, Coffield AB, Edwards NM, Goodman MJ.
Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med. ; – [Google Scholar] Brennan A, Chick SE, Davies R.
A taxonomy of model structures for economic evaluation of health technologies. Health by: The cost-effectiveness of inactivated influenza vaccination in reducing influenza illness, hospitalization, and death is well established in persons aged 65 years or older, a group that is at increased risk of severe influenza-related complications.
However, the benefits of annual influenza vaccination of healthy adults younger than 65 Cited by: Cost-effectiveness analyses offer a relatively inexpensive and responsive method of evaluating new vaccination strategies.
For example, a cost-effectiveness analysis has demonstrated that high-dose trivalent influenza vaccine is economically reasonable for use in individuals ≥65 years of age, given its increased by: 4. The cost-effectiveness of vaccines is influenced by several factors, including vaccine efficacy and durability, severity of disease burden, vaccine price, and delivery-program by: "The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community," N Eng J Med () iv CDC, National Center for Health Statistics, Mortality Data from the National Vital Statistic System.
WHO has developed a unique set of resource documents, that can support countries to assess the economic burden of disease, cost of introduction and the cost effectiveness of influenza vaccination.
Influenza economics guidance and tools; Risk groups Maternal influenza immunization. inWHO, cast a wide net among research institutions.
Per Vaccination Cost-Effectiveness Ratios for Annual Influenza Vaccination Among High-Risk Persons Compared to Ratios Among the General Population, Through 29 Effect on Medicare Costs of Annual Influenza Vaccination for Persons 65 Years and Older.
Flu (influenza) immunisation service. Flu vaccines are given as a needle and are only available on their own (not as a combination vaccine). They can be provided by a variety of recognised immunisation providers.
If you're eligible, you can get the influenza vaccine for free under the National Immunisation Program (NIP).There is a clinical need for more effective influenza vaccines in this population.
This study evaluated the cost-effectiveness of an MF59®-adjuvanted trivalent influenza vaccine (aTIV) in adults aged over 65 years in Argentina compared with the non-adjuvanted trivalent influenza vaccine (TIV) used under the current national vaccination policy.